UK launches trial of drug to tackle fatigue in long Covid patients
by Linda Geddes Science correspondent from Science | The Guardian on (#5RF7K)
AXA1125 targets cell power plants that may be dysfunctional in long Covid patients with severe fatigue
The first trial of a drug to target the fatigue and muscle weakness experienced by more than half of people with long Covid has been launched in the UK. It is also the first drug trial in long Covid patients who were not hospitalised during their initial infection.
The drug, called AXA1125, targets cellular power plants called mitochondria, which it is thought could be dysfunctional in the subset of long Covid patients with severe fatigue. If successful, it could pave the way for similar trials in patients with other forms of post-viral fatigue, including myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS).
Continue reading...